There is an increasing recognition that Keap1/Nrf2 pathway activation can be beneficial for DCM, as it has been recognized as a key regulator of anti-oxidant defense system by mediating the expression of anti-oxidant genes, such as HO-1, GCLC, NAPD-H, and NQO-1. The gene discussed is NQO1; the disease is familial dilated cardiomyopathy.